Investing
Now valued at more than $1 billion, the startup provides virtual care and local support services to patients who may otherwise fall through the cracks.
The company plans on using the funds to add new capabilities including billing and payment collection.
The startup will be targeting new hires, increased marketing and brand awareness campaigns, and new developments for its product.
The company will be headed by Verily's cofounder Tom Stanis.
This comes roughly a year after the company raised $113 million in Series B funding.
The company currently has three prescription digital therapeutics available on the market.
Also: Stanford University spinout Deepcell lands $20 million in funding and Folx raises $4.4 million.
The company projects that sales of its testing kits will triple by the end of 2020.
The company also announced that it is expanding into the Asia Pacific region.
The funding will be used to expand its new prescription therapeutic under the German Digital Healthcare Act.